Strategy

Jul 18, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In the wake of a high-profile death from counterfeit drugs, the industry reacts
Jul 03, 2007
Pharmaceutical Executive
What's old and established is in, what's new—and once interpreted as"better"—is out
Jul 03, 2007
Pharmaceutical Executive
It's bittersweet being one of the leaders of an industry that is not sustainable," a top pharma CEO recently told Carolyn Buck Luce, Ernst & Young's global pharmaceutical sector leader. Bittersweet is a poignant word for a hard-driving exec to issue.
Jun 27, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Global market will be twice as big by 2020, but industry needs new vision
Jun 01, 2007
Pharmaceutical Executive
It was like the end of the arms race last November when Pfizer announced it was slashing its national sales force by 20 percent. Coolly downplayed as cost-cutting by new CEO Jeffrey Kindler, the stunning move was met by industry insiders, Wall Street analysts, and the media with one humongous collective sigh of relief. Big Pharma was seen as having grown dangerously addicted to the detailing game over the past decade, with the top firms plowing more and more of their blockbuster profits into trying to keep up with Pfizer's "flood the zone" strategy and with less and less to show for it.
Jun 01, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.
Jun 01, 2007
Pharmaceutical Executive
To harness consumerization to improve the industry's image and enhance the value of its products, pharma leaders need to focus on the "Four Cs": commitment, choice, collaboration, and customization
May 23, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Beneficiaries don't switch back to brands after trying generics.
May 01, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Today's highest science, most fierce competition—and make no mistake, biggest gains—are coming from the oncology arena. In fact, there are more than 380 cancer compounds in development, according to a recent report by IMS Health, with almost 100 of them in Phase III trials.
Apr 25, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Drug industry leads in 'world class' competitive intelligence.
native1_300x100
lorem ipsum